Cancer Screening

Liquid Biopsy, or Circulating Tumor Cells, May Help the Diagnosis of Early-Stage Cancer and Minimal Residual Disease Detection

Wayne Kuznar

April 2018, Vol 8, No 4 - Cancer Screening

Measuring circulating tumor (ct)DNA in the blood, a so-called liquid biopsy, may be used to detect minimal residual ­disease (MRD) after definitive treatment, as well as to predict disease relapse throughout the course of treatment. Other emerging applications include assessment of response, detection of treatment resistance, early detection of cancer, and tumor classification, said Ash A. Alizadeh, MD, PhD, Assistant Professor of Medicine, Divisions of Oncology and Hematology, Stanford Cancer Institute, at the 2018 Gastrointestinal Cancers Symposium. [ Read More ]